ArticleBMC cancer2015

Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.

Benoît Thézé et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.